Gennaro Pagano, MD, MSc, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland, King’s College London, London, UK, gives an overview of current therapies under development targeting alpha-synuclein (α-syn) in Parkinson’s disease. These strategies include targeting extracellular aggregated α-syn, as well as intracellular components and α-syn production. In addition, gene therapies to replace one of the mutated α-syn copies or to interfere with the production of α-syn are also currently being developed. Finally, Dr Pagano mentions therapeutic approaches acting on other pathways involved in α-syn aggregation. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy).